What is US NUCLEAR CORP's earnings per share (EPS)?

US NUCLEAR CORP (UCLE) reported diluted earnings per share of -$0.02 for fiscal year 2025. This represents a 50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

US NUCLEAR CORP (UCLE) Financials

UCLE

Trailing 12 months to March 31, 2026

Revenue $2.0M +0.3% YoY

Net Income -$866K +59.5% YoY

EPS (Diluted) -$0.02 0.0% YoY

Operating Cash Flow -$233K +54.5% YoY

Market Cap $1.6M as of Oct 14, 2026

Price / Sales 0.8x on $2.0M revenue, trailing 12 months to March 31, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to March 31, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q1 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Oct 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed Oct 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UCLE SEC filings page.

US NUCLEAR CORP (UCLE) reported $2.0M in revenue over the twelve months to Mar 31, 2026, up 0.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UCLE FY2025 2026-10-04

Revenue is roughly flat, but 2025 margin recovery still leaves the company dependent on liabilities and financing inflows.

Revenue remained essentially unchanged from FY2024 to FY2025, yet operating margin improved from -70.1% to -43.3%; this indicates the year's progress came from better margin and expense performance, not sales expansion. That matters because the business is improving its economics within a largely fixed sales base rather than growing its way out of the operating-cost burden.

Gross margin recovery from 37.7% in FY2022 to 50.3% in FY2025 has not yet produced operating breakeven. Operating loss was $939K in FY2025, indicating the fixed expense base remains large relative to this revenue scale.

Operating cash flow was -$199K, nearly matched by a financing inflow of $203K, so reported cash movement depended nearly as much on financing as operations. The balance sheet remained strained: liabilities exceeded assets and the current ratio was 0.7x, while the supplied liquidity measure represented 8.1 months of annual operating outflow.

Financial Health Signals

Financial health score not available

US NUCLEAR CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-15.93

US NUCLEAR CORP scores -15.93, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.6M) relative to total liabilities ($2.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

US NUCLEAR CORP passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

US NUCLEAR CORP reported a net loss of $1.2M while operations used $199K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

US NUCLEAR CORP reported an operating loss of $939K against $162K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$352K

YoY-26.1%

QoQ-45.8%

5Y CAGR-3.4%

10Y CAGR+3.4%

US NUCLEAR CORP generated $352K in revenue in Q1 2026. This represents a decrease of 26.1% from the same quarter a year earlier. Against the prior quarter it is down 45.8%.

EBITDA

-$145K

YoY+72.2%

QoQ-20727.9%

US NUCLEAR CORP's EBITDA was -$145K in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 72.2% from the same quarter a year earlier. Against the prior quarter it is down 20727.9%.

Net Income

-$187K

YoY+66.6%

QoQ+69.7%

US NUCLEAR CORP reported -$187K in net income in Q1 2026. This represents an increase of 66.6% from the same quarter a year earlier. Against the prior quarter it is up 69.7%.

EPS (Diluted)

$0.00

YoY-100.0%

QoQ+100.0%

US NUCLEAR CORP earned $0.00 per diluted share (EPS) in Q1 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is up 100.0%.

Cash & Balance Sheet

Cash & Debt

$67K

YoY-1.7%

QoQ-50.1%

5Y CAGR-28.6%

US NUCLEAR CORP held $67K in cash against $523K in long-term debt as of Q1 2026.

Shares Outstanding

63M

YoY+5.4%

QoQ+2.3%

US NUCLEAR CORP had 63M shares outstanding in Q1 2026. This represents an increase of 5.4% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

44.0%

YoY-29.2pp

QoQ+14.3pp

5Y change-4.1pp

10Y change-4.4pp

US NUCLEAR CORP's gross margin was 44.0% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 29.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.3 percentage points.

Operating Margin

-41.4%

QoQ-41.3pp

10Y change+1.4pp

US NUCLEAR CORP's operating margin was -41.4% in Q1 2026, reflecting core business profitability. Against the prior quarter it is down 41.3 percentage points. No change is given against Q1 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

-53.1%

QoQ+42.0pp

10Y change-8.4pp

US NUCLEAR CORP's net profit margin was -53.1% in Q1 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 42.0 percentage points. No change is given against Q1 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q1 2026.

Capital Allocation

None of these metrics is reported for Q1 2026.

UCLE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UCLE quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.0M	$2.2M-1.0%	$2.2M-1.8%	$2.2M+6.7%	$2.1M-2.2%	$2.1M+21.9%	$1.8M-50.5%	$3.5M-2.6%	$3.6M+18.4%	$3.1M+46.4%	$2.1M-20.9%	$2.7M+62.0%	$1.6M-30.5%	$2.4M-9.8%	$2.6M-13.5%	$3.0M
Cost of Revenue	$1.1M	$1.1M-8.2%	$1.2M-10.1%	$1.3M+0.3%	$1.3M+71.3%	$761K-40.5%	$1.3M-20.4%	$1.6M-6.0%	$1.7M-1.1%	$1.7M+30.5%	$1.3M+6.1%	$1.2M+37.7%	$905K-25.9%	$1.2M-4.3%	$1.3M-20.2%	$1.6M
Gross Profit	$896K	$1.1M+7.4%	$1.0M+9.9%	$924K+17.3%	$788K-42.8%	$1.4M+190.1%	$475K-75.5%	$1.9M+0.4%	$1.9M+43.3%	$1.3M+73.7%	$774K-45.0%	$1.4M+92.1%	$732K-35.3%	$1.1M-15.0%	$1.3M-6.0%	$1.4M
SG&A Expenses	$477K	$1.0M-36.9%	$1.7M+20.7%	$1.4M+66.0%	$830K+25.2%	$663K+131.2%	$287K-51.5%	$591K-81.7%	$3.2M+146.8%	$1.3M+17.2%	$1.1M+13.8%	$982K-5.3%	$1.0M-27.5%	$1.4M+76.8%	$809K-22.4%	$1.0M
Operating Income	-$561K	-$939K+38.8%	-$1.5M+6.5%	-$1.6M-9.7%	-$1.5M-9.8%	-$1.4M+34.6%	-$2.1M+15.3%	-$2.5M-2.9%	-$2.4M-7044.0%	$34K+102.2%	-$1.6M-473.6%	$424K+239.3%	-$305K-2.1%	-$298K-157.0%	$524K+39.6%	$375K
EBITDA	N/A	-$938K+38.8%	-$1.5M+6.4%	-$1.6M-9.8%	-$1.5M-9.8%	-$1.4M+34.7%	-$2.1M+15.3%	-$2.5M-5.4%	-$2.3M-1415.5%	$177K+111.8%	-$1.5M-447.7%	$431K+244.9%	-$297K-0.9%	-$295K-154.4%	$542K+37.1%	$395K
Interest Expense	$167K	$162K-28.1%	$225K-26.6%	$307K+380.6%	$64K+481.0%	$11K-76.0%	$46K-26.9%	$63K+112.6%	$29K+21.3%	$24K+16.7%	$21K-16.3%	$25K+47.8%	$17K+261.7%	$5K-37.9%	$8K-57.5%	$18K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	N/A	N/A	$25K	N/A
Net Income	-$866K	-$1.2M+28.8%	-$1.7M+49.3%	-$3.4M-68.1%	-$2.0M-8.9%	-$1.9M+47.0%	-$3.5M-11.9%	-$3.2M-31.3%	-$2.4M-23861.8%	$10K+100.6%	-$1.6M-502.1%	$399K+224.2%	-$322K-1006.9%	-$29K-105.9%	$491K+37.4%	$358K
EPS (Basic)	N/A	-$0.02+50.0%	-$0.04+60.0%	-$0.10-42.9%	-$0.070.0%	-$0.07	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00	N/A
EPS (Diluted)	-$0.02	-$0.02+50.0%	-$0.04+60.0%	-$0.10-42.9%	-$0.070.0%	-$0.07	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	60M+29.3%	47M+29.7%	36M+22.2%	30M+7.8%	27M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$352K-26.1%	$650K+44.7%	$595K-2.5%	$447K-11.0%	$477K-24.1%	$449K-30.1%	$611K+2.9%	$503K+44.9%
Cost of Revenue	$197K+54.3%	$457K-11.8%	$296K+114.1%	$198K-19.0%	$128K-53.4%	$518K-20.8%	$138K+8.3%	$244K-21.8%
Gross Profit	$155K-55.6%	$193K+379.1%	$299K-36.7%	$249K-3.5%	$349K-1.4%	-$69K-490.3%	$473K+1.5%	$258K+645.8%
SG&A Expenses	$301K-65.5%	-$787K-97114.9%	$558K+2.9%	$405K-34.8%	$873K+75.2%	$811+100.2%	$542K+0.4%	$622K+3.5%
Operating Income	-$146K+72.1%	-$1K+99.9%	-$258K-273.5%	-$156K+57.0%	-$524K-262.7%	-$958K-36.5%	-$69K+6.0%	-$363K+35.8%
EBITDA	-$145K+72.2%	-$698+99.9%	-$258K-280.1%	-$156K+57.1%	-$524K-264.5%	-$958K-36.6%	-$68K+7.2%	-$363K+35.7%
Interest Expense	$41K+13.3%	$29K-46.9%	$69K+66.0%	$28K-70.0%	$36K-2.3%	$54K-77.0%	$42K+50.2%	$92K+345.2%
Net Income	-$187K+66.6%	-$618K+38.9%	$147K+232.9%	-$208K+54.4%	-$560K-245.9%	-$1.0M+11.1%	-$111K+85.4%	-$455K+47.7%
EPS (Basic)	$0.00+100.0%	-$0.01+50.0%	$0.00	-$0.010.0%	-$0.01	-$0.02+33.3%	$0.00+100.0%	-$0.01+50.0%
EPS (Diluted)	$0.00-100.0%	-$0.01+50.0%	$0.00	-$0.01	$0.01	-$0.02+33.3%	$0.00+100.0%	-$0.01+50.0%
Diluted Shares (Avg)	63M+9.4%	N/A	64M+32.6%	48M	57M+34.8%	N/A	48M+32.2%	45M+27.6%

Not reported in any period shown, so not listed: R&D Expenses, Income Tax.

UCLE Balance Sheet

UCLE quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.9M-27.4%	$2.6M-7.4%	$2.9M-8.1%	$3.1M+9.0%	$2.9M+16.1%	$2.5M-30.7%	$3.5M+6.1%	$3.3M+25.1%	$2.7M+9.3%	$2.4M-30.3%	$3.5M+10.5%	$3.2M+10.4%	$2.9M+19.4%	$2.4M+29.4%	$1.9M
Current Assets	$1.5M-28.6%	$2.1M-9.1%	$2.3M-9.1%	$2.5M+11.6%	$2.2M+24.5%	$1.8M-34.4%	$2.7M0.0%	$2.8M+35.1%	$2.0M+22.1%	$1.7M-42.9%	$2.9M+13.1%	$2.6M+13.4%	$2.3M+25.6%	$1.8M+45.1%	$1.2M
Cash & Equivalents	$135K+3.0%	$131K-14.4%	$153K+21.2%	$126K-48.8%	$246K+8.4%	$227K-79.1%	$1.1M+12.2%	$969K+119.1%	$442K+87.1%	$236K-43.6%	$419K+198.8%	$140K-47.2%	$266K-23.7%	$348K+111.3%	$165K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.1M-29.5%	$1.5M-12.8%	$1.8M-13.0%	$2.0M+13.0%	$1.8M+36.0%	$1.3M+20.0%	$1.1M+4.8%	$1.0M-20.4%	$1.3M+9.5%	$1.2M-48.2%	$2.3M-1.0%	$2.3M+64.9%	$1.4M+25.6%	$1.1M+28.2%	$883K
Accounts Receivable	$214K-39.2%	$351K+2.7%	$342K+3.7%	$330K+101.7%	$164K-35.9%	$255K-54.5%	$560K-23.3%	$731K+162.8%	$278K+21.3%	$229K+26.6%	$181K+89.2%	$96K-83.6%	$585K+75.5%	$333K+64.9%	$202K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$440K-22.9%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K
Total Liabilities	$2.4M-30.5%	$3.5M-27.6%	$4.8M+40.0%	$3.5M+43.5%	$2.4M+49.9%	$1.6M-12.7%	$1.8M+38.4%	$1.3M-1.9%	$1.4M+16.1%	$1.2M+54.2%	$757K-12.5%	$866K-29.4%	$1.2M+70.9%	$718K+8.1%	$664K
Current Liabilities	$2.2M-19.3%	$2.7M-44.3%	$4.8M+40.0%	$3.5M+43.5%	$2.4M+60.6%	$1.5M+21.0%	$1.2M+39.2%	$890K-1.4%	$903K+8.5%	$832K+63.6%	$509K-37.0%	$808K+42.8%	$566K+45.5%	$389K-23.4%	$508K
Non-Current Liabilities	$259K-67.8%	$805K	$0	$0	$0-100.0%	$108K-82.1%	$601K+36.6%	$440K-2.9%	$453K+34.7%	$336K+35.1%	$249K+327.5%	$58K-91.2%	$660K+100.8%	$329K+110.6%	$156K
Long-Term Debt	$532K-64.8%	$1.5M+165.1%	$570K	N/A	N/A	N/A	$55K+28.7%	$43K-26.3%	$58K	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$514K+40.0%	-$856K+56.8%	-$2.0M-469.2%	-$348K-178.9%	$441K-47.9%	$847K-50.2%	$1.7M-15.2%	$2.0M+53.1%	$1.3M+3.2%	$1.3M-53.7%	$2.7M+19.2%	$2.3M+40.1%	$1.6M-2.5%	$1.7M+41.2%	$1.2M
Retained Earnings	-$21.1M-7.5%	-$19.7M-6.0%	-$18.6M-22.7%	-$15.1M-15.8%	-$13.1M-17.3%	-$11.1M-46.5%	-$7.6M-71.2%	-$4.4M-118.3%	-$2.0M+0.5%	-$2.0M-366.2%	-$439K+47.7%	-$838K-62.2%	-$517K-6.0%	-$487K+50.2%	-$979K

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$1.6M-34.4%	$1.9M-27.4%	$2.5M-17.7%	$2.5M-11.9%	$2.5M-14.1%	$2.6M-7.4%	$3.1M-0.7%	$2.8M-4.4%
Current Assets	$1.2M-37.8%	$1.5M-28.6%	$2.0M-21.7%	$1.9M-14.8%	$1.9M-17.5%	$2.1M-9.1%	$2.5M-0.1%	$2.3M-4.8%
Cash & Equivalents	$67K-1.7%	$135K+3.0%	$76K+138.9%	$46K-66.4%	$68K-48.2%	$131K-14.4%	$32K-82.8%	$138K+43.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.0M-42.5%	$1.1M-29.5%	$1.7M-13.3%	$1.8M-0.3%	$1.8M-1.9%	$1.5M-12.8%	$2.0M-4.7%	$1.8M-8.3%
Accounts Receivable	$83K+35.7%	$214K-39.2%	$130K-72.0%	$39K-86.2%	$61K-84.3%	$351K+2.7%	$464K+91.6%	$280K-4.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$440K-22.9%	$440K-22.9%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%	$570K0.0%
Total Liabilities	$2.4M-25.2%	$2.4M-30.5%	$2.4M-25.9%	$3.3M-36.9%	$3.2M-36.1%	$3.5M-27.6%	$3.2M-26.2%	$5.2M+24.8%
Current Liabilities	$2.2M-7.9%	$2.2M-19.3%	$2.2M-7.3%	$2.5M-52.5%	$2.4M-52.3%	$2.7M-44.3%	$2.4M-44.8%	$5.2M+24.8%
Non-Current Liabilities	$193K-76.1%	$259K-67.8%	$155K-81.0%	$805K	$805K	$805K	$816K	$0
Long-Term Debt	$523K-56.1%	$532K-64.8%	$347K-45.6%	$1.1M+64.2%	$1.2M+80.5%	$1.5M+165.1%	$638K	$664K
Total Equity	-$740K-8.4%	-$514K+40.0%	$146K+200.6%	-$751K+67.5%	-$683K+67.0%	-$856K+56.8%	-$146K+88.5%	-$2.3M-99.6%
Retained Earnings	-$21.4M-5.5%	-$21.1M-7.5%	-$20.5M-10.1%	-$20.6M-11.3%	-$20.3M-12.7%	-$19.7M-6.0%	-$18.6M-6.7%	-$18.5M-10.9%

UCLE Cash Flow Statement

UCLE quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$233K	-$199K+60.8%	-$509K-93.2%	-$263K+80.1%	-$1.3M-200.2%	-$441K+28.2%	-$614K-370.2%	-$131K+66.9%	-$395K-340.1%	$164K+157.7%	-$285K-382.3%	$101K+121.8%	-$464K+13.1%	-$534K-6066.3%	$9K-98.0%	$457K
Depreciation & Amortization	N/A	$1K-36.1%	$2K-28.3%	$3K-2.4%	$3K+25.2%	$3K+28.3%	$2K+34.0%	$1K-97.5%	$60K-58.3%	$143K+64.0%	$87K+1228.9%	$7K-10.6%	$7K+98.5%	$4K-80.0%	$18K-8.9%	$20K
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1K	N/A
Capital Expenditures	N/A	N/A	N/A	$858	N/A	$6K	N/A	$4K-37.8%	$6K+190.4%	$2K	$0	N/A	$1K-80.7%	$6K	N/A	$20K
Free Cash Flow	N/A	N/A	N/A	-$264K	N/A	-$447K	N/A	-$134K+66.5%	-$401K-346.6%	$162K+157.0%	-$285K	N/A	-$465K+13.9%	-$540K	N/A	$437K
Investing Cash Flow	N/A	N/A	-$31K-25.3%	-$25K	N/A	-$21K+90.9%	-$235K+53.3%	-$504K-3091.9%	-$16K-693.2%	-$2K+96.7%	-$60K	$0+100.0%	-$1K+80.7%	-$6K+91.8%	-$79K+74.1%	-$304K
Financing Cash Flow	$232K	$203K-60.7%	$518K+64.5%	$315K-73.9%	$1.2M+150.0%	$481K+4396.3%	-$11K-101.5%	$753K-19.7%	$937K+2055.1%	$43K-73.2%	$162K-8.7%	$178K-47.6%	$339K-25.9%	$457K+80.7%	$253K+322.1%	-$114K
Dividends Paid	$141K	$29K-35.8%	$46K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$7K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$127K-36.8%	-$103K-23.7%	$150K+163.5%	-$154K-52.9%	-$92K-4.4%	-$84K+48.1%	-$236K-369.2%	-$100K+60.8%
Depreciation & Amortization	$524+45.6%	$360+113.0%	$360-72.2%	$360	$360-54.3%	$169-78.8%	$1K+199.3%	$0-100.0%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$9K-144.5%	-$4K-180.0%	-$14K-371.0%
Financing Cash Flow	$59K+96.1%	$162K-15.4%	-$121K-190.0%	$131K+9.3%	$30K-58.1%	$192K+44.2%	$134K+5675.1%	$120K-14.6%
Dividends Paid	$199K+127.5%	$0	-$96K	$38K	$87K	N/A	N/A	N/A
Share Buybacks	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow.

UCLE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UCLE quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	50.3%+3.9pp	46.4%+4.9pp	41.4%+3.7pp	37.7%-26.7pp	64.4%+37.3pp	27.1%-27.6pp	54.6%+1.6pp	53.0%+9.2pp	43.8%+6.9pp	36.9%-16.1pp	53.0%+8.3pp	44.7%-3.4pp	48.1%-3.0pp	51.1%+4.1pp	47.0%
Operating Margin	-43.3%+26.8pp	-70.1%+3.5pp	-73.6%-2.0pp	-71.5%-7.8pp	-63.7%	-118.9%	-69.5%-3.7pp	-65.8%-66.9pp	1.1%+76.7pp	-75.6%-91.6pp	16.0%+34.6pp	-18.6%-5.9pp	-12.7%-32.8pp	20.1%+7.6pp	12.4%
Net Margin	-57.1%+22.3pp	-79.4%	-153.9%	-97.7%-9.9pp	-87.8%	-201.8%	-89.3%-23.1pp	-66.2%-66.6pp	0.3%+76.9pp	-76.6%-91.7pp	15.1%+34.7pp	-19.6%-18.4pp	-1.2%-20.1pp	18.8%+7.0pp	11.8%
Return on Equity	N/A	N/A	N/A	N/A	-425.3%-7.7pp	-417.6%-231.7pp	-185.9%-65.9pp	-120.0%-120.8pp	0.8%+127.3pp	-126.5%-141.1pp	14.6%+28.5pp	-14.0%-12.2pp	-1.8%-31.0pp	29.2%-0.8pp	30.0%
Return on Assets	-64.5%+1.3pp	-65.7%+54.4pp	-120.2%-54.5pp	-65.7%+0.1pp	-65.8%+78.3pp	-144.1%-54.9pp	-89.3%-17.1pp	-72.2%-72.5pp	0.4%+66.3pp	-65.9%-77.3pp	11.4%+21.6pp	-10.2%-9.1pp	-1.0%-21.5pp	20.5%+1.2pp	19.3%
Current Ratio	0.68-0.1x	0.77+0.3x	0.47-0.3x	0.73-0.2x	0.93-0.3x	1.20-1.0x	2.22-0.9x	3.09+0.8x	2.26+0.3x	2.00-3.7x	5.74+2.5x	3.20-0.8x	4.02-0.6x	4.66+2.2x	2.46
Debt-to-Equity	N/A	N/A	N/A	N/A	5.46+3.6x	1.90+1.9x	0.030.0x	0.020.0x	0.04-0.9x	0.92+0.6x	0.28-0.1x	0.38-0.4x	0.75+0.3x	0.43-0.1x	0.56
Asset Turnover	1.13+0.3x	0.830.0x	0.78+0.1x	0.67-0.1x	0.750.0x	0.71-0.3x	1.00-0.1x	1.09-0.1x	1.15+0.3x	0.86+0.1x	0.76+0.2x	0.52-0.3x	0.82-0.3x	1.09-0.5x	1.63
FCF Margin	N/A	N/A	-11.8%	N/A	-20.9%	N/A	-3.8%+7.2pp	-11.0%-16.3pp	5.3%+18.9pp	-13.6%	N/A	-28.4%-5.4pp	-22.9%	N/A	14.5%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	44.0%-29.2pp	29.7%+45.1pp	50.2%-27.1pp	55.8%+4.3pp	73.2%+16.8pp	-15.4%-13.6pp	77.4%-1.1pp	51.4%+41.4pp
Operating Margin	-41.4%	-0.2%	-43.4%-32.1pp	-34.9%+37.4pp	-109.9%	-213.3%	-11.3%+1.1pp	-72.3%
Net Margin	-53.1%	-95.2%	24.8%+42.9pp	-46.5%+44.1pp	-117.5%	-225.2%	-18.2%	-90.6%
Return on Equity	N/A	N/A	100.7%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-11.4%+11.0pp	-32.2%+6.0pp	5.8%+9.4pp	-8.3%+7.7pp	-22.4%-16.9pp	-38.2%+1.6pp	-3.6%+20.9pp	-16.0%+13.3pp
Current Ratio	0.55-0.3x	0.68-0.1x	0.88-0.2x	0.79+0.3x	0.81+0.3x	0.77+0.3x	1.04+0.5x	0.44-0.1x
Debt-to-Equity	N/A	N/A	2.37	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.210.0x	0.34+0.2x	0.230.0x	0.180.0x	0.190.0x	0.17-0.1x	0.200.0x	0.18+0.1x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$514K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.68), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
US NUCLEAR CORP UCLE	FY2025	$2.2M	-$1.2M	-57.1%	$1.6M	—
TRACK GROUP INC TRCK	FY2025	$35.2M	-$1.9M	-5.3%	$19.0M	—
SATIVUS TECH CORP SATT	FY2025	N/A	-$869K	N/A	$907K	—
SCIENTIFIC INDUSTRIES INC SCND	FY2025	$5.1M	-$1.2M	-24.1%	$8.2M	—
DARKPULSE INC DPLS	FY2025	$308K	-$3.0M	N/A	$906K	—
LIFELOC TECHNOLOGIES INC LCTC	FY2025	$9.0M	-$2.5M	-27.4%	$11.0M	—

Where US NUCLEAR CORP Ranks

Frequently Asked Questions

What is US NUCLEAR CORP's annual revenue?

US NUCLEAR CORP (UCLE) reported $2.2M in total revenue for fiscal year 2025. This represents a -1.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is US NUCLEAR CORP's revenue growing?

US NUCLEAR CORP (UCLE) revenue declined by 1.0% year-over-year, from $2.2M to $2.2M in fiscal year 2025.

Is US NUCLEAR CORP profitable?

No, US NUCLEAR CORP (UCLE) reported a net income of -$1.2M in fiscal year 2025, with a net profit margin of -57.1%.

What is US NUCLEAR CORP's EBITDA?

US NUCLEAR CORP (UCLE) had EBITDA of -$938K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does US NUCLEAR CORP have?

As of fiscal year 2025, US NUCLEAR CORP (UCLE) had $135K in cash and equivalents against $532K in long-term debt.

What is US NUCLEAR CORP's gross margin?

US NUCLEAR CORP (UCLE) had a gross margin of 50.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is US NUCLEAR CORP's operating margin?

US NUCLEAR CORP (UCLE) had an operating margin of -43.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is US NUCLEAR CORP's net profit margin?

US NUCLEAR CORP (UCLE) had a net profit margin of -57.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is US NUCLEAR CORP's operating cash flow?

US NUCLEAR CORP (UCLE) recorded an outflow of $199K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are US NUCLEAR CORP's total assets?

US NUCLEAR CORP (UCLE) had $1.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Does US NUCLEAR CORP buy back shares?

Yes, US NUCLEAR CORP (UCLE) spent $7K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does US NUCLEAR CORP have outstanding?

US NUCLEAR CORP (UCLE) had 61M shares outstanding as of fiscal year 2025.

What is US NUCLEAR CORP's current ratio?

US NUCLEAR CORP (UCLE) had a current ratio of 0.68 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is US NUCLEAR CORP's return on assets (ROA)?

US NUCLEAR CORP (UCLE) had a return on assets of -64.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is US NUCLEAR CORP's P/E ratio?

US NUCLEAR CORP (UCLE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2026). The market capitalization is $1.6M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is US NUCLEAR CORP's price-to-sales ratio?

US NUCLEAR CORP (UCLE) trades at 0.8x sales, its market capitalization divided by revenue of $2.0M revenue, trailing 12 months to March 31, 2026. The market capitalization is $1.6M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does US NUCLEAR CORP's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, US NUCLEAR CORP (UCLE) held $135K in cash, cash equivalents and investments, and reported an operating cash outflow of $199K over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is US NUCLEAR CORP's debt-to-equity ratio negative or not reported?

US NUCLEAR CORP (UCLE) has negative shareholder equity of -$514K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is US NUCLEAR CORP's Altman Z-Score?

US NUCLEAR CORP (UCLE) has an Altman Z-Score of -15.93, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is US NUCLEAR CORP's Piotroski F-Score?

US NUCLEAR CORP (UCLE) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are US NUCLEAR CORP's earnings high quality?

US NUCLEAR CORP (UCLE) reported a net loss of $1.2M while operations used $199K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can US NUCLEAR CORP cover its interest payments?

US NUCLEAR CORP (UCLE) reported an operating loss of $939K against $162K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.